Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

PERRIGO COMPANY (PRGO)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 4 885 M
EBIT 2017 975 M
Net income 2017 352 M
Debt 2017 2 819 M
Yield 2017 0,75%
Sales 2018 5 000 M
EBIT 2018 1 032 M
Net income 2018 504 M
Debt 2018 2 281 M
Yield 2018 0,77%
P/E ratio 2017 35,56
P/E ratio 2018 20,99
EV / Sales2017 3,08x
EV / Sales2018 2,90x
Capitalization 12 211 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
11/30Ex-dividend day
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
11/23 PERRIGO : Completes Divestiture Of API Business For $110 Million
11/21 PERRIGO : Completes Divestiture Of API Business For $110 Million
11/10 PERRIGO : to Present at the Stifel 2017 Healthcare Conference
11/09 PERRIGO : Announces Tentative FDA Approval for a First-to-File Generic Version o..
11/09 PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
11/09 S&P 500 MOVERS : Ctl, coty
11/09 PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
11/09 PERRIGO : beats Street 3Q forecasts
11/09 PERRIGO COMPANY PLC : Reports Third Quarter 2017 Financial Results
11/08 Short seller Kerrisdale targets Woodford-backed Prothena
More news
Sector news : Pharmaceuticals - NEC
09:31aDJBAYER : Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
11/23 German chemicals companies should review British ops - trade body
11/23DJGLAXOSMITHKLINE : Files Additional Trelegy Ellipta Application to FDA
11/22 BAYER : Brazil pushes back decision on Bayer-Monsanto tie-up
11/22 European shares retreat on euro bounce; UK flat after budget
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 87,9 $
Spread / Average Target 1,4%
EPS Revisions
Managers
NameTitle
John T. Hendrickson Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY12 211
JOHNSON & JOHNSON20.08%368 832
NOVARTIS12.75%219 874
ROCHE HOLDING LTD.4.90%215 394
PFIZER9.42%211 188
MERCK AND COMPANY-7.64%148 286